Abbott Labs Still Unvervalued, Now Less Threatened by Lawsuit

By John Mylant: Abbott Laboratories (ABT) has continuously been moving up in a nice stepping pattern for the last year. As we get closer to its spin-off, new information on the company's drug Humira should continue to make the stock increase in value. Let's look at two major factors I believe should keep the stock bullish for the foreseeable future. Humira Factor

By Dividend Kings:Abbott Laboratories (ABT) has been on a pretty good run recently. The company's year-over-year second quarter earnings per share increased by 38%, and over the last 52 weeks, the stock price has increased by 28%. The biggest revenue driver for Abbott is Humira. Humira is the blockbuster drug that is used to treat rheumatoid arthritis, psoriatic arthritis and chronic plaque psoriasis.

By Bret Jensen:The market has had a nice run over the past week and a half. However, I still remain cautious; there are still many shoes to drop in Europe, and domestic economic growth seems like it will be tepid at best through the rest of 2011. For the time being, I am sticking with stocks with low valuations, steadily growing earnings and solid and increasing dividend yields.

Dividend Growth Investor submits:Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.

By Trefis: Abbott Labs (ABT) is going to announce its Q3 results on Oct. 17. It is the third major healthcare company in our coverage to announce its results after Roche Holdings (RHHBY.OB) and Johnson & Johnson (JNJ) announces its earnings on Oct. 16.

Abbott's (ABT) planned separation remains on track for year end, creating two stand alone companies: AbbVie, with the drug portfolio and pipeline, and Abbott, with nutritional products and devices. Investors may want to pick up shares of Abbott beforehand, particularly to gain exposure to AbbVie's thick drug pipeline.

ByTroy Bayer:A recent study by The National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) revealed that Abbott Laboratories' (ABT) Niaspan was ineffective in reducing the likelihood of heart attacks in patients with cardiovascular disease.

Analytical Chemist submits:Johnson & Johnson (JNJ) and Abbott Labs (ABT) are both large, diversified pharmaceutical and health care companies. While both have impressive records of sales, earnings, and dividend increases, Abbott Labs is a much better investment.